

**HIROTSU Bioscience Inc.****New Director/CSO Appointed for Overseas Growth Strategy**

– Welcomed Barret Comiskey, inventor of electronic ink and serial entrepreneur –

**We as HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”)) are pleased to announce that Barrett Comiskey, a serial entrepreneur, and inventor of electronic ink used in products such as the Amazon Kindle, has been appointed as Director and Chief Strategy Officer (CSO) as of December 21.**

Up to this time, we have been conducting research and development to create a future in which cancers can be detected at an early stage. With life expectancy continuing to increase around the world, cancer has become an issue of international importance. N-NOSE<sup>®</sup> is one of the few technologies that can solve this problem because it is simple, highly accurate, and inexpensive. Therefore, we have invited Barrett Comiskey to join our Board of Directors and CSO to expand N-NOSE<sup>®</sup> beyond Japan and into the global market.

Barrett Comiskey invented electronic ink, the technology used in products such as the Amazon Kindle, while studying at the Massachusetts Institute of Technology. This technology, for which he has been awarded 75 patents, is considered one of the greatest innovations since letterpress printing in the 15th century. Since then, the technology has evolved beyond books, with new applications ranging from electronic shelf labels to outdoor signage. In addition to being an inventor, he is also the co-founder of E Ink, the company based on the electronic ink technology, that has since grown to a market capitalization of approximately \$6 billion (about 0.9 trillion yen) in less than 10 years. Since then, he has established a wide range of experience and achievements by starting businesses in different fields not only in the U.S. but also in China, Taiwan, and Southeast Asia. Going forward, we will leverage his experiences and work together to implement the overseas expansion of "N-NOSE"

■ Comment from Barrett Comiskey

Dr. Hirotsu's invention – reimagining a very common model biological organism to be a high-fidelity biosensor that can solve one of the biggest social problems in the world - is an amazing example of thinking outside of fixed ideas which immediately resonated with me as a lifelong lateral-thinker.

The potential of an affordable, non-invasive, highly sensitive test that can detect “silent killer cancers” at early stages is poised to change the face of cancer screening worldwide and save millions of lives, avoiding the suffering of millions more.

When I met the team and felt their deep commitment to this important project, I felt a moral imperative to support Dr.Hirotsu and his mission. This is why it is truly an honor to officially become part of this team as its Chief Strategy Officer, to support Dr. Hirotsu in actualizing his vision in the most effective, efficient, and scalable way. HBS has already done an amazing job in Japan, and I believe that with my experience in the US and a number of other countries, we can successfully open the largest markets on the planet and accelerate Early Cancer Detection worldwide.

#### ■Career



He graduated from the Massachusetts Institute of Technology in 1997 with a B.S. in Mathematics. While in school, he invented electronic ink, which is used in e-readers like Amazon Kindle. Based on this technology, he founded E Ink, Inc. a company that has since grown to a market capitalization of approximately \$6 billion. In 2004, he earned an MBA from Stanford Graduate School of Business. He was recognized as a Technology Pioneer by the World Economic Forum and was the youngest inductee into the National Inventors Hall of Fame.

#### ■About HIROTSU Bio Science

We as HIROTSU aim to protect the health and future security of people through research, development, and practical application of unique technology that utilize the capabilities of living organisms. Established in 2016, N-NOSE was put to practical use thanks to our researchers' abundance of ideas and tireless efforts. Despite the importance of extending healthy life expectancy being emphasized, it is said that one in every two people will be diagnosed with cancer in this age of 100-year life expectancy. We will contribute to solving these social issues with the world's first groundbreaking technology that utilizes the power of nematodes, which have a superior sense of smell that no artificial device can match.

Company Name: HIROTSU Bio Science Inc.

Headquarters: New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo

Name of Representative: Takaaki Hirotsu, CEO

Date of Establishment: August 2016

Main Service: Research, development, and marketing of cancer screenings using nematode and nematode olfactory sensors

Corporate website: <https://hbio.jp/en/>

#### ■About “N-NOSE”

A primary cancer screening test that utilizes the highly accurate detection of cancer-specific odors in human urine by the nematode *C. elegans*, which has an excellent sense of smell. By just submitting urine, it is a simple, inexpensive, highly accurate, and comprehensive systemic cancer test. The test has been proven to detect 15 types of cancer: oral cavity pharynx cancer, esophagus cancer, lung cancer, breast cancer, stomach cancer, liver cancer, pancreas cancer, gall bladder cancer, bile duct cancer, colon cancer, kidney cancer, bladder cancer, ovary cancer, uterus cancer, prostate cancer, etc. Since its launch in January 2020, a total of over 500,000 people have been tested. The number of corporate customers has exceeded 1,700 (as of July 2023). From 2023, we also launched "N-NOSE plus Pancreas" as a next-generation "cancer type specific test" of N-NOSE, and "N-NOSE Dog" and "N-NOSE Cat" as cancer risk tests for pets.

Official service website : <https://lp.n-nose.com/>